Contact coating of prostheses

Details Contact coating of prostheses Contact coating of prostheses

2005-12-06

2005-12-06

Walczak, David J. (Department: 3751)

Coating implements with material supply

Including ball, roller or endless-belt tool

C401S009000, C118S227000, C118S244000, C118S258000

Reexamination Certificate

active

06971813

ABSTRACT:
A method and apparatus for coating prostheses via contact patterning with an applicator. Applicators can include rollers, tampons, and ribbons. Coating materials include a variety of substances including polymers and therapeutic agents.

REFERENCES:
patent: 2464040 (1949-03-01), Huebner
patent: 5298276 (1994-03-01), Jayaraman
patent: 5763330 (1998-06-01), Bertolucci et al.
patent: 5773081 (1998-06-01), Williamitis et al.
patent: 5925259 (1999-07-01), Biebuyck et al.
patent: 6190077 (2001-02-01), Newson et al.
patent: 6352768 (2002-03-01), Hseih et al.
patent: 6355058 (2002-03-01), Pacetti et al.
patent: 6413318 (2002-07-01), Yoo et al.
patent: 6428853 (2002-08-01), Eriksson
patent: 02/14078 (2002-02-01), None
Adler, L.M., et al., “Analysis of exposure times and dose escalation of paclitaxel in ovarian cancer cell lines,”Cancer74(7):1891-1898, Abstract only, 1994.
“Basic Theory: How does transfer pad printing work?,” http://www.itwtranstech.com/pages/how.html, Trans Tech America Inc., 2002.
Farb, Andrew, “Comparative Pathology of Drug Eluting Stents: Insights Into Effectiveness and Toxicity from the Animal Lab,” Presentation from CRF Drug-Eluting Stent Symposium, http://tctmd.com/expert-presentations, 2002.
Hiatt, Bonnie L. et al., “Drug-Eluting Stents for Prevention of Restenosis: In Quest for the Holy Grail,”Catheterization and Cardiovascular Interventions55:409-417, 2002.
Kalinowski, M., et al., “Paclitaxel inhibits proliferation of cell lines responsible for metal stent obstruction: Possible topical application in malignant bile duct obstructions,”Invest Radiol37(7):399-404, Abstract only, 2002.
Kandzari, David E., et al., “Highlights from the American Heart Association Annual Scientific Sessions 2001: Nov. 11-14, 2001,”American Heart Journal143(2):217-228, 2002.
Liebmann, J.E., et al., “Cytotoxic studies of paclitaxel (Taxol) in human tumor cell lines,”Br J Cancer68(6):1104-1109, Abstract only, 1993.
Regar, E., et al., “Stent development and local drug delivery,”Br Med Bull59:227-248, Abstract only, 2001.
Taxol Quanam Data and the SCORE study, Grube E. (the effect of taxol on the edges of the stent and dose response screening) 6-7. ISET 2002 Miami Beach, Mar. 19-23, 2002.
Sirolimus: Pre-clinical studies—Evaluatin of dosing, efficacy and toxicity. Andrew J. and Carter D.O., TCT Sep. 2001.

Affiliated with

Also associated with

Rating

Contact coating of prostheses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Contact coating of prostheses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Contact coating of prostheses will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3471492